RU2017121896A - Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты - Google Patents
Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты Download PDFInfo
- Publication number
- RU2017121896A RU2017121896A RU2017121896A RU2017121896A RU2017121896A RU 2017121896 A RU2017121896 A RU 2017121896A RU 2017121896 A RU2017121896 A RU 2017121896A RU 2017121896 A RU2017121896 A RU 2017121896A RU 2017121896 A RU2017121896 A RU 2017121896A
- Authority
- RU
- Russia
- Prior art keywords
- dosage form
- oral dosage
- microsporiosiosis
- form according
- ssp
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 1
- 201000008827 tuberculosis Diseases 0.000 claims 12
- 239000006186 oral dosage form Substances 0.000 claims 8
- 208000030852 Parasitic disease Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- 208000004554 Leishmaniasis Diseases 0.000 claims 2
- 206010024229 Leprosy Diseases 0.000 claims 2
- 241000243985 Onchocerca volvulus Species 0.000 claims 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 claims 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 2
- 239000007962 solid dispersion Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 claims 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 208000004881 Amebiasis Diseases 0.000 claims 1
- 206010001980 Amoebiasis Diseases 0.000 claims 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 1
- 240000005528 Arctium lappa Species 0.000 claims 1
- 241000223838 Babesia bovis Species 0.000 claims 1
- 241000223846 Babesia canis Species 0.000 claims 1
- 241001455947 Babesia divergens Species 0.000 claims 1
- 241000223848 Babesia microti Species 0.000 claims 1
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical compound [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 claims 1
- 241001408365 Besnoitia darlingi Species 0.000 claims 1
- 206010056377 Bone tuberculosis Diseases 0.000 claims 1
- 241000191796 Calyptosphaeria tropica Species 0.000 claims 1
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 1
- 241000037164 Collema parvum Species 0.000 claims 1
- 208000008953 Cryptosporidiosis Diseases 0.000 claims 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 claims 1
- 241000016605 Cyclospora cayetanensis Species 0.000 claims 1
- 241000205707 Cystoisospora belli Species 0.000 claims 1
- 241001126690 Cytauxzoon felis Species 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 241000223924 Eimeria Species 0.000 claims 1
- 241000224432 Entamoeba histolytica Species 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 201000006353 Filariasis Diseases 0.000 claims 1
- 206010016675 Filariasis lymphatic Diseases 0.000 claims 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 claims 1
- 241000406101 Hammondia Species 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 241000222738 Leishmania aethiopica Species 0.000 claims 1
- 241000222740 Leishmania braziliensis Species 0.000 claims 1
- 241000222697 Leishmania infantum Species 0.000 claims 1
- 208000037263 Lymphatic filariasis Diseases 0.000 claims 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 claims 1
- 206010027259 Meningitis tuberculous Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 claims 1
- ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 claims 1
- 244000020186 Nymphaea lutea Species 0.000 claims 1
- 240000009188 Phyllostachys vivax Species 0.000 claims 1
- 241000223821 Plasmodium malariae Species 0.000 claims 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 claims 1
- 241001505293 Plasmodium ovale Species 0.000 claims 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 241000242678 Schistosoma Species 0.000 claims 1
- 241000242683 Schistosoma haematobium Species 0.000 claims 1
- 239000004187 Spiramycin Substances 0.000 claims 1
- 241000223777 Theileria Species 0.000 claims 1
- 206010044269 Toxocariasis Diseases 0.000 claims 1
- 241000223996 Toxoplasma Species 0.000 claims 1
- 241000223997 Toxoplasma gondii Species 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 206010044608 Trichiniasis Diseases 0.000 claims 1
- 241000223104 Trypanosoma Species 0.000 claims 1
- 208000001008 Tuberculous Pericarditis Diseases 0.000 claims 1
- 208000022971 Tuberculous meningitis Diseases 0.000 claims 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims 1
- BDVURRFCMBLHTJ-GKCQJNIGSA-M [Sb](=O)(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)[O-].[Na+] Chemical compound [Sb](=O)(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)[O-].[Na+] BDVURRFCMBLHTJ-GKCQJNIGSA-M 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 229960003942 amphotericin b Drugs 0.000 claims 1
- 229910052787 antimony Inorganic materials 0.000 claims 1
- 229940075103 antimony Drugs 0.000 claims 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 claims 1
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 claims 1
- 229960003159 atovaquone Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- 201000008680 babesiosis Diseases 0.000 claims 1
- 229960004001 benznidazole Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical group ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 1
- 229960002227 clindamycin Drugs 0.000 claims 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 229960003722 doxycycline Drugs 0.000 claims 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000005239 filarial elephantiasis Diseases 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000006592 giardiasis Diseases 0.000 claims 1
- 229960003242 halofantrine Drugs 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007227 lymph node tuberculosis Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 229960001962 mefloquine Drugs 0.000 claims 1
- 229960001728 melarsoprol Drugs 0.000 claims 1
- 208000001223 meningeal tuberculosis Diseases 0.000 claims 1
- 201000011475 meningoencephalitis Diseases 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229960002644 nifurtimox Drugs 0.000 claims 1
- 208000002042 onchocerciasis Diseases 0.000 claims 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims 1
- 229960004448 pentamidine Drugs 0.000 claims 1
- 201000006485 pericardial tuberculosis Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960005179 primaquine Drugs 0.000 claims 1
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims 1
- 229960005385 proguanil Drugs 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims 1
- 229960000611 pyrimethamine Drugs 0.000 claims 1
- 229960001404 quinidine Drugs 0.000 claims 1
- 229960000948 quinine Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 229960001294 spiramycin Drugs 0.000 claims 1
- 229930191512 spiramycin Natural products 0.000 claims 1
- 235000019372 spiramycin Nutrition 0.000 claims 1
- -1 su lfonamide Chemical compound 0.000 claims 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004306 sulfadiazine Drugs 0.000 claims 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims 1
- 229960005314 suramin Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000003982 trichinellosis Diseases 0.000 claims 1
- 201000007588 trichinosis Diseases 0.000 claims 1
- 201000002311 trypanosomiasis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Dispersion Chemistry (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161534841P | 2011-09-14 | 2011-09-14 | |
| US61/534,841 | 2011-09-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014114499A Division RU2627471C2 (ru) | 2011-09-14 | 2012-09-13 | Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017121896A true RU2017121896A (ru) | 2019-01-29 |
Family
ID=46964044
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017121896A RU2017121896A (ru) | 2011-09-14 | 2012-09-13 | Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты |
| RU2014114499A RU2627471C2 (ru) | 2011-09-14 | 2012-09-13 | Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014114499A RU2627471C2 (ru) | 2011-09-14 | 2012-09-13 | Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9884042B2 (enExample) |
| EP (1) | EP2765993B1 (enExample) |
| JP (3) | JP2014526508A (enExample) |
| KR (1) | KR20140063808A (enExample) |
| CN (1) | CN105142615A (enExample) |
| AU (1) | AU2012308663B2 (enExample) |
| CA (1) | CA2848493A1 (enExample) |
| CL (1) | CL2014000623A1 (enExample) |
| ES (1) | ES2803524T3 (enExample) |
| IL (1) | IL231462A0 (enExample) |
| MX (1) | MX356105B (enExample) |
| PH (1) | PH12014500593A1 (enExample) |
| RU (2) | RU2017121896A (enExample) |
| SG (1) | SG11201400632YA (enExample) |
| WO (1) | WO2013040120A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2842946C2 (ru) * | 2021-06-02 | 2025-07-04 | Нихон Нохияку Ко., Лтд. | Производное бензимидазола или его соль, содержащее его средство для борьбы с филярозом собак и способ его применения |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2765993B1 (en) | 2011-09-14 | 2020-05-20 | Amgen (Europe) GmbH | Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| EP3089736B1 (en) * | 2013-12-31 | 2025-07-23 | Ascendia Pharmaceuticals, LLC | Pharmaceutical compositions for poorly water-soluble compounds |
| WO2015175505A1 (en) * | 2014-05-15 | 2015-11-19 | Lundbeck Llc | Tetrabenazine modified release formulation |
| US20170087129A1 (en) * | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
| KR101722564B1 (ko) * | 2014-09-16 | 2017-04-03 | 강원대학교산학협력단 | 수-난용성 약물을 포함하는 고체분산체 |
| EP3308792A4 (en) * | 2015-06-12 | 2018-09-12 | Nissan Chemical Industries, Ltd. | Calcium salt composition and filaggrin production promoter using same |
| AU2019321583C1 (en) | 2018-08-17 | 2025-11-27 | Eidos Therapeutics, Inc. | Formulations of AG10 |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| KR20230079151A (ko) * | 2020-10-01 | 2023-06-05 | 이마고 바이오사이언시즈 인코포레이티드 | Kdm1a 에 의해 매개되는 질환 치료용 약학 제형 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| PT2177517E (pt) | 1996-07-24 | 2011-11-10 | Celgene Corp | 2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| HN1998000115A (es) | 1997-08-21 | 1999-06-02 | Warner Lambert Co | Formas de dosificación farmacéuticas sólidas |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| AU2002343220A1 (en) | 2001-11-09 | 2003-05-19 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US20100129363A1 (en) | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| NZ548049A (en) | 2003-12-02 | 2009-01-31 | Celgene Corp | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| MXPA06010699A (es) | 2004-03-22 | 2006-12-15 | Celgene Corp | Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel. |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| JP2007533761A (ja) | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物 |
| CA2598204C (en) * | 2004-11-09 | 2015-01-13 | Board Of Regents, The University Of Texas System | Stabilized hme composition with small drug particles |
| ZA200704784B (en) | 2004-11-12 | 2008-10-29 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| CA2588597A1 (en) | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| JP2009507030A (ja) | 2005-09-01 | 2009-02-19 | セルジーン・コーポレーション | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
| WO2008138755A2 (en) | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for poorly soluble drugs |
| ES2393640T3 (es) * | 2008-02-13 | 2012-12-26 | Dainippon Sumitomo Pharma Co., Ltd. | Comprimidos bucodisgregables |
| MX2010010334A (es) * | 2008-03-24 | 2010-10-08 | Celgene Corp | Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida. |
| CA2734646C (en) | 2008-08-20 | 2016-06-28 | James W. Mcginity | Hot-melt extrusion of modified release multi-particulates |
| CA2736171A1 (en) | 2008-09-10 | 2010-03-18 | Celgene Corporation | Processes for the preparation of aminosulfone compounds |
| MY160002A (en) | 2009-02-10 | 2017-02-15 | Celgene Corp | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
| US9023886B2 (en) * | 2009-11-10 | 2015-05-05 | Celgene Corporation | Nanosuspension of a poorly soluble drug via microfluidization process |
| NZ600123A (en) * | 2009-11-30 | 2015-04-24 | Aptalis Pharmatech Inc | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture |
| WO2012096859A2 (en) | 2011-01-10 | 2012-07-19 | Celgene Corporation | Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide |
| EP2765993B1 (en) | 2011-09-14 | 2020-05-20 | Amgen (Europe) GmbH | Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide |
| HUE050327T2 (hu) | 2011-12-27 | 2020-11-30 | Amgen Europe Gmbh | Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal |
-
2012
- 2012-09-13 EP EP12766778.0A patent/EP2765993B1/en active Active
- 2012-09-13 SG SG11201400632YA patent/SG11201400632YA/en unknown
- 2012-09-13 KR KR1020147009799A patent/KR20140063808A/ko not_active Ceased
- 2012-09-13 RU RU2017121896A patent/RU2017121896A/ru unknown
- 2012-09-13 PH PH1/2014/500593A patent/PH12014500593A1/en unknown
- 2012-09-13 JP JP2014530765A patent/JP2014526508A/ja not_active Ceased
- 2012-09-13 CN CN201280055703.3A patent/CN105142615A/zh active Pending
- 2012-09-13 AU AU2012308663A patent/AU2012308663B2/en active Active
- 2012-09-13 MX MX2014003261A patent/MX356105B/es active IP Right Grant
- 2012-09-13 WO PCT/US2012/054990 patent/WO2013040120A1/en not_active Ceased
- 2012-09-13 US US14/344,870 patent/US9884042B2/en active Active
- 2012-09-13 ES ES12766778T patent/ES2803524T3/es active Active
- 2012-09-13 CA CA2848493A patent/CA2848493A1/en not_active Abandoned
- 2012-09-13 RU RU2014114499A patent/RU2627471C2/ru active
-
2014
- 2014-03-11 IL IL231462A patent/IL231462A0/en unknown
- 2014-03-14 CL CL2014000623A patent/CL2014000623A1/es unknown
-
2017
- 2017-02-01 JP JP2017016400A patent/JP6339251B2/ja active Active
- 2017-05-26 JP JP2017104141A patent/JP2017178961A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2842946C2 (ru) * | 2021-06-02 | 2025-07-04 | Нихон Нохияку Ко., Лтд. | Производное бензимидазола или его соль, содержащее его средство для борьбы с филярозом собак и способ его применения |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150190374A1 (en) | 2015-07-09 |
| CA2848493A1 (en) | 2013-03-21 |
| JP2017178961A (ja) | 2017-10-05 |
| RU2627471C2 (ru) | 2017-08-08 |
| HK1200356A1 (en) | 2015-08-07 |
| SG11201400632YA (en) | 2014-04-28 |
| US9884042B2 (en) | 2018-02-06 |
| JP2014526508A (ja) | 2014-10-06 |
| IL231462A0 (en) | 2014-04-30 |
| MX2014003261A (es) | 2014-04-10 |
| JP6339251B2 (ja) | 2018-06-06 |
| EP2765993B1 (en) | 2020-05-20 |
| KR20140063808A (ko) | 2014-05-27 |
| EP2765993A1 (en) | 2014-08-20 |
| AU2012308663B2 (en) | 2017-06-08 |
| ES2803524T3 (es) | 2021-01-27 |
| JP2017105804A (ja) | 2017-06-15 |
| AU2012308663A1 (en) | 2014-04-03 |
| RU2014114499A (ru) | 2015-10-20 |
| CL2014000623A1 (es) | 2014-11-07 |
| WO2013040120A1 (en) | 2013-03-21 |
| CN105142615A (zh) | 2015-12-09 |
| PH12014500593A1 (en) | 2019-09-02 |
| MX356105B (es) | 2018-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raes et al. | Alternatively activated macrophages in protozoan infections | |
| Su et al. | Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection | |
| Bustamante et al. | Trypanosoma cruzi reinfections in mice determine the severity of cardiac damage | |
| JP2017105804A5 (enExample) | ||
| Akoolo et al. | Protozoan co-infections and parasite influence on the efficacy of vaccines against bacterial and viral pathogens | |
| Lee et al. | Unforeseen pathologies caused by malaria | |
| de Meis et al. | Differential regional immune response in Chagas disease | |
| Ajjampur et al. | Cryptosporidium species in HIV-infected individuals in India: an overview | |
| Malla et al. | Pathophysiology of visceral leishmaniasis-some recent concepts | |
| Guedes et al. | Nitric oxide donor trans‐[RuCl ([15] aneN4) NO] 2+ as a possible therapeutic approach for Chagas' disease | |
| Onkoba et al. | Malaria endemicity and co-infection with tissue-dwelling parasites in Sub-Saharan Africa: a review | |
| Escobedo et al. | Treatment of intestinal protozoan infections in children | |
| Ji et al. | Toxoplasma gondii: effects of exogenous nitric oxide on egress of tachyzoites from infected macrophages | |
| Malaguarnera et al. | Plasma levels of interleukin‐18 and interleukin‐12 in Plasmodium falciparum malaria | |
| Gazzinelli et al. | Induction of cell-mediated immunity during early stages of infection with intracellular protozoa | |
| Nyakundi et al. | Protective effect of chronic schistosomiasis in baboons coinfected with Schistosoma mansoni and Plasmodium knowlesi | |
| TW200819431A (en) | Use of triazinetrione sulphones for controlling coccidioses | |
| Rodríguez-Angulo et al. | Etanercept induces low QRS voltage and autonomic dysfunction in mice with experimental Chagas disease | |
| Collins et al. | The Chesson strain of Plasmodium vivax in humans and different species of Aotus monkeys | |
| Pereira et al. | Hypertrophy of NADH-diaphorase positive myenteric neurons in rat jejunum after acute infection caused by Toxoplasma gondii | |
| Butcher | T-cell depletion and immunity to malaria in HIV-infections | |
| Ramharter et al. | Plasmodium falciparum‐specific interleukin‐2 and tumor necrosis factor‐α expressing‐T cells are associated with resistance to reinfection and severe malaria in healthy African children | |
| CA2579779A1 (en) | Method for multiple sclerosis treatment and prophylaxis by treatment of leptospira infection | |
| Mewono et al. | Malaria antigen-mediated enhancement of interleukin-21 responses of peripheral blood mononuclear cells in African adults | |
| Serna et al. | Finding of leishmanicidal activity of 14-hydroxylunularin in mice experimentally infected with Leishmania infantum |